These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 32314085

  • 1. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
    Täger T, Atar D, Agewall S, Katus HA, Grundtvig M, Cleland JGF, Clark AL, Fröhlich H, Frankenstein L.
    Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
    [Abstract] [Full Text] [Related]

  • 2. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T, Hadnorntun P, Leelahavarong P, Kongmalai P, Srinonprasert V, Chirakarnjanakorn S, Chaikledkaew U, McKay G, Attia J, Thakkinstian A.
    Front Endocrinol (Lausanne); 2023 Nov; 14():1216160. PubMed ID: 38179304
    [Abstract] [Full Text] [Related]

  • 3. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
    Täger T, Frankenstein L, Atar D, Agewall S, Frey N, Grundtvig M, Clark AL, Cleland JGF, Fröhlich H.
    Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
    [Abstract] [Full Text] [Related]

  • 4. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 5. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis].
    Tian L, Wang QY, Sun RM, Qi MM, Li YX, Gao X, Zhang LQ, Ma X, Shi H, Yu J, Bai F.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct 24; 49(10):1000-1011. PubMed ID: 34674438
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
    Riaz M, Smith SM, Dietrich EA, Winchester DE, Guo J, Park H.
    Pharmacotherapy; 2023 Oct 24; 43(10):1024-1031. PubMed ID: 37459069
    [Abstract] [Full Text] [Related]

  • 7. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
    Luo Y, Bai R, Zhang W, Qin G.
    Front Endocrinol (Lausanne); 2024 Oct 24; 15():1333624. PubMed ID: 38362282
    [Abstract] [Full Text] [Related]

  • 8. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
    Chen L, Xue Q, Yan C, Tang B, Wang L, Zhang B, Zhao Q.
    Front Endocrinol (Lausanne); 2023 Oct 24; 14():1256548. PubMed ID: 38027214
    [Abstract] [Full Text] [Related]

  • 9. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y.
    Adv Ther; 2019 Oct 24; 36(10):2567-2586. PubMed ID: 31444707
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY, Liu SY, Yin DG.
    Medicine (Baltimore); 2021 Jul 30; 100(30):e26431. PubMed ID: 34397684
    [Abstract] [Full Text] [Related]

  • 11. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
    Li X, Wu H, Peng H, Jiang H.
    Front Endocrinol (Lausanne); 2022 Jul 30; 13():1078686. PubMed ID: 36589800
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Arbel R, Aboalhasan E, Hammerman A, Azuri J.
    Am J Cardiol; 2021 Jul 01; 150():65-68. PubMed ID: 34001339
    [Abstract] [Full Text] [Related]

  • 13. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC.
    BMJ Open Diabetes Res Care; 2019 Dec 01; 7(1):. PubMed ID: 32043472
    [Abstract] [Full Text] [Related]

  • 14. Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
    Odutayo A, da Costa BR, Pereira TV, Garg V, Iskander S, Roble F, Lalji R, Hincapié CA, Akingbade A, Rodrigues M, Agarwal A, Lawendy B, Saadat P, Udell JA, Cosentino F, Grant PJ, Verma S, Jüni P.
    J Am Heart Assoc; 2021 Sep 21; 10(18):e019918. PubMed ID: 34514812
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ.
    Diabetes Obes Metab; 2016 Aug 21; 18(8):783-94. PubMed ID: 27059700
    [Abstract] [Full Text] [Related]

  • 16. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX, Liu LY, Zhang CX, Geng XH, Gu SM, Wang YQ, Liu H, Xie Q, Liang S.
    Front Endocrinol (Lausanne); 2023 Aug 21; 14():1238399. PubMed ID: 37701900
    [Abstract] [Full Text] [Related]

  • 17. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
    Chen JY, Pan HC, Shiao CC, Chuang MH, See CY, Yeh TH, Yang Y, Chu WK, Wu VC.
    Cardiovasc Diabetol; 2023 Oct 27; 22(1):290. PubMed ID: 37891550
    [Abstract] [Full Text] [Related]

  • 18. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
    Riaz M, Guo J, Smith SM, Dietrich EA, Winchester DE, Park H.
    Am J Cardiovasc Drugs; 2024 May 27; 24(3):455-464. PubMed ID: 38691312
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
    Tian L, Ai S, Zheng H, Yang H, Zhou M, Tang J, Liu W, Zhao W, Wang Y.
    Front Pharmacol; 2022 May 27; 13():986186. PubMed ID: 36506550
    [Abstract] [Full Text] [Related]

  • 20. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials.
    Wang F, Li C, Cui L, Gu S, Zhao J, Wang H.
    Front Endocrinol (Lausanne); 2024 May 27; 15():1436217. PubMed ID: 39247919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.